How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

748 results for

Prophylactic Oophorectomy

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations. (PubMed)

. Concomitantly, risk-reducing strategies should be analyzed: surgical or pharmacological. When prophylactic bilateral salpingo-oophorectomy is performed before menopause, estrogen replacement therapy could be required. For BRCA, we review the risks of cancer in mutations carriers, criteria for genetic testing, surveillance and risk-reduction strategies, and the safety of prescribing hormone therapy when needed.

2018 Climacteric

182. Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA<sup>1-/ 2-</sup> carriers. (PubMed)

levels of CDK2 confirms growth inhibition by reversibly arresting cell-cycle progression at the G1-S phase, not by inducing apoptosis.Our study showed an anti-proliferative effect on ovarian BRCA1-/2- MSC on in vitro combined treatment with mifepristone and progesterone. These findings suggest that mifepristone or other selective progesterone receptor modulators could be developed as a preventive treatment and postpone early use of prophylactic salpingo-oophorectomy as well as reduce the risk

2018 Acta Obstetricia et Gynecologica Scandinavica

183. Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

salpingectomy or bilateral oophorectomy). If male, is surgically sterile or willing to use highly effective birth control upon enrollment, during the treatment period, and for 6 months following the last dose of investigational drug or cytarabine, whichever is later. Exclusion criteria: Has diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO classification of APL with translocation, t(15;17)(q22;q12), or BCR-ABL positive leukemia (ie, chronic myelogenous (...) for central nervous system (CNS) leukostasis Prophylactic intrathecal chemotherapy Growth factor or cytokine support Has received prior treatment with any investigational product or device within 30 days prior to enrollment in the study or is currently participating in other investigational procedures Has a history of other malignancies excluding the following: Adequately treated non-melanoma skin cancer Curatively treated in situ disease, or other solid tumors curatively treated with no evidence

2018 Clinical Trials

184. Unusual Cancers of Childhood Treatment (PDQ®): Health Professional Version

be considered to decrease permanent damage to those structures.[ ] Total thyroidectomy also optimizes the use of radioactive iodine for imaging and treatment. Central neck dissection: A therapeutic central neck lymph node dissection should be done in the presence of clinical evidence of central or lateral neck metastases.[ ] For patients without clinical evidence of gross extrathyroidal invasion or locoregional metastasis, a prophylactic central neck dissection may be considered on the basis of tumor (...) focality and size of the primary tumor. However, because of the increased morbidity associated with central lymph node dissection, it is important to carefully individualize each case on the basis of the risks and benefits of the extent of dissection.[ ] Lateral neck dissection: Cytological confirmation of metastatic disease to lymph nodes in the lateral neck is recommended before surgery. Routine prophylactic lateral neck dissection is not recommended. Classification and risk assignment.[ ] Despite

2016 PDQ - NCI's Comprehensive Cancer Database

185. Ovarian Epithelial Cancer Treatment (PDQ®): Health Professional Version

at increased risk, prophylactic oophorectomy may be considered after age 35 years if childbearing is complete. In a family-based study among 551 women with BRCA1 or BRCA2 mutations, of the 259 women who had undergone bilateral prophylactic oophorectomy, 2 (0.8%) developed subsequent papillary serous peritoneal carcinoma, and 6 (2.8%) had stage I ovarian cancer at the time of surgery. Of the 292 matched controls, 20% who did not have prophylactic surgery developed ovarian cancer. Prophylactic surgery (...) was associated with a reduction in the risk of ovarian cancer that exceeded 90% (relative risk, 0.04; 95% confidence interval, 0.01–0.16), with an average follow-up of 9 years;[ ] however, family-based studies may be associated with biases resulting from case selection and other factors that influence the estimate of benefit.[ ] After a prophylactic oophorectomy, a small percentage of women may develop a primary peritoneal carcinoma that is similar in appearance to ovarian cancer.[ ] (Refer to the section

2016 PDQ - NCI's Comprehensive Cancer Database

186. Genetics of Colorectal Cancer (PDQ®): Health Professional Version

with the syndrome. For example, regular has been shown to improve survival. Prophylactic surgery (colectomy) has also been shown to improve survival in . The timing and extent of risk-reducing surgery usually depends on the number of polyps, their size, histology, and symptomatology. For and a diagnosis of CRC, extended resection is associated with fewer metachronous CRCs and additional surgical procedures for colorectal neoplasia than in patients who undergo segmental resection for CRC. The surgical decision

2016 PDQ - NCI's Comprehensive Cancer Database

187. Breast Cancer Treatment (PDQ®): Health Professional Version

of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383 (9922): 1041-8, 2014. [ ] Hartmann LC, Schaid DJ, Woods JE, et al.: Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340 (2): 77-84, 1999. [ ] Rebbeck TR, Levin AM, Eisen A, et al.: Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91 (17): 1475-9 (...) , 1999. [ ] Kauff ND, Satagopan JM, Robson ME, et al.: Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 (21): 1609-15, 2002. [ ] Rebbeck TR, Lynch HT, Neuhausen SL, et al.: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (21): 1616-22, 2002. [ ] Kauff ND, Domchek SM, Friebel TM, et al.: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter

2016 PDQ - NCI's Comprehensive Cancer Database

188. Genetics of Breast and Ovarian Cancer (PDQ®): Health Professional Version

observational Million Women’s Study in the United Kingdom.[ ] The risk of breast cancer was not elevated, however, in women randomly assigned to estrogen-only versus placebo in the WHI study (RR, 0.77; 95% CI, 0.59–1.01). Eligibility for the estrogen-only arm of this study required hysterectomy, and 40% of these patients also had undergone oophorectomy, which potentially could have impacted breast cancer risk.[ ] The association between HRT and breast cancer risk among women with a family history of breast (...) tested for BRCA1/BRCA2 pathogenic variants.[ ] Short-term use of hormones for treatment of menopausal symptoms appears to confer little or no breast cancer risk.[ , ] The effect of HRT on breast cancer risk among carriers of BRCA1 or BRCA2 pathogenic variants has been studied in the context of bilateral risk-reducing oophorectomy, in which short-term replacement does not appear to reduce the protective effect of oophorectomy on breast cancer risk.[ ] (Refer to the section of this summary for more

2016 PDQ - NCI's Comprehensive Cancer Database

190. Breast Cancer Prevention (PDQ®): Health Professional Version

produced an overestimate. Study Design : Evidence obtained from case-control and cohort studies. Internal Validity : Good. Consistency : Good. External Validity : Good. Prophylactic oophorectomy or ovarian ablation: benefits Based on solid evidence, premenopausal women with BRCA gene mutations who undergo prophylactic oophorectomy have lower breast cancer incidence. Similarly, oophorectomy or ovarian ablation is associated with decreased breast cancer incidence in normal premenopausal women (...) and in women with increased breast cancer risk resulting from thoracic irradiation. Magnitude of Effect : Breast cancer incidence is decreased by 50%, but published study designs may have produced an overestimate. Study Design : Observational, case-control, and cohort studies. Internal Validity : Good. Consistency : Good. External Validity : Good. Prophylactic oophorectomy or ovarian ablation: harms Based on solid evidence, castration may cause the abrupt onset of menopausal symptoms such as hot flashes

2016 PDQ - NCI's Comprehensive Cancer Database

191. Cancer Genetics Risk Assessment and Counseling (PDQ®): Health Professional Version

. For example, bilateral salpingo-oophorectomy in a premenopausal woman significantly reduces the risk of ovarian and breast cancers. This may mask underlying hereditary predisposition to these cancers. Current age (if living). Age at death and cause of death (if deceased). Carcinogenic exposures (e.g., alcohol and tobacco use, sun exposure, radiation exposure, asbestos exposure) or other known cancer site-specific risk factors. Prior germline genetic testing results. Prior tumor testing results (including

2016 PDQ - NCI's Comprehensive Cancer Database

192. Breast cancer susceptibility 1 and 2 (BRCA1/2) gene testing for hereditary breast and ovarian cancer (HBOC)

), prophylactic mastectomy and salpingo-oophorectomy, and chemoprevention. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Genes, BRCA1; Genes, BRCA2s; Genetic Predisposition to Disease; Ovarian Neoplasms Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215

2013 Health Technology Assessment (HTA) Database.

193. Vaginal brachytherapy for treatment of women with high-intermediate risk of endometrial cancer

radiotherapy remains uncertain. Although EBRT and VBT provide similar improvement in vaginal recurrence, it is not clear that this outcome translates to overall or disease-free survival exceeding surgery alone. If radiotherapy is to be performed at all, the indication at present is that prophylactic VBT should be sufficient to reduce the majority of vaginal recurrence following total abdominal hysterectomy with bilateral salpingo-oophorectomy while resulting in fewer toxic effects than EBRT. HEALTHPACT (...) bleeding patterns among women who are pre- menopausal. The majority of women with endometrial cancer present with FIGO 1 stage I disease (Shepherd 1989) and have good prognosis with overall survival approaching 90 per cent. With the exception of women with locally advanced or metastatic disease, the standard of treatment is complete abdominal hysterectomy with bilateral salpingo- oophorectomy (surgical removal of the fallopian tubes and ovaries). The decision to give adjuvant treatments such as VBT

2011 Australia and New Zealand Horizon Scanning Network

194. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers

available to breast cancer (BRCA) 1 and BRCA2 gene mutation carriers aged 30 years or older, who had no cancer diagnosis. Interventions The interventions were: prophylactic mastectomy, prophylactic bilateral salpingo-oophorectomy (BSO), prophylactic mastectomy and BSO (both surgeries), tamoxifen, mammography, mammography plus magnetic resonance imaging (MRI), and prophylactic BSO plus MRI. Location/setting USA/hospital and secondary care. Methods Analytical approach: The analysis was based on a Markov (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of primary and secondary preventive interventions for breast cancer (BRCA) 1 and BRCA2 gene mutation carriers aged 30 years or older, with no cancer diagnosis. The authors concluded that bilateral salpingo-oophorectomy (BSO

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

195. A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

test (by serum beta-HCG) within 7 days prior to the start of treatment. Female of childbearing potential must be surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation), abstinent (at the discretion of the investigator), or agree to use adequate contraception since signing of the informed consent form until at least 3 months after the last study drug administration. Females of childbearing potential are those who have not been surgically sterilized or have not been (...) of bleeding within 28 days prior to enrollment. Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, arterial thrombosis) within 6 months prior to enrollment. Use of aspirin (>325 mg/day) within 10 days prior to the first dose of study treatment. The use of prophylactic therapeutic anti-coagulants are allowed provided that INR or aPTT are within therapeutic limits (according to the medical standard of the enrollment institution) and patient has been on a stable dose of anticoagulants

2017 Clinical Trials

196. Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

her treating physician immediately. Male patients who father a child should notify the treating physician. NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria: Has not undergone a hysterectomy or bilateral oophorectomy Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months) Patients must have the ability (...) to understand and the willingness to sign a written informed consent prior to registration on study. Diagnosis must be made by surgical excision. Patients should not be on antibiotics for any infection but post operative antibiotics are allowed if used prophylactically but should be completed prior to starting RT. EXCLUSION CRITERIA: Patients who are receiving any other investigational agents. Known history of immunodeficiency (HIV). This medical entity can be exacerbated by PD-1 blockade. Any form

2017 Clinical Trials

197. Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

for > 2 years Amenorrheic for < 2 years without a hysterectomy and/or oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation Post hysterectomy, oophorectomy or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure. For female patients of childbearing potential (...) for at least 2 week at the time of study enrollment. Prophylactic use of anticoagulants is allowed. Severe infections ≤ 4 weeks prior to Cycle 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia Signs or symptoms of infection ≤ 2 weeks prior to Cycle 1, Day 1 Received oral or IV antibiotics ≤ 2 weeks prior to Cycle 1, Day 1 - Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic

2017 Clinical Trials

198. Pulmonary sarcomatoid_MEDI4736+Treme

- Absolute neutrophil count 1,500 cells/mm3, platelets 100,000 cells/mm3 Expected survival ≥ 3 months Female subjects must either be of non-reproductive potential (ie, post-menopausal by history: ≥60 years old and no menses for ≥1 year without an alternative medical cause; or history of hysterectomy, or history of bilateral tubal ligation, or history of bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry. Exclusion Criteria: A patient with no measurable disease chronic (...) requiring therapy history of Human Immunodeficiency Virus (HIV) active Hepatitis B or C (inactive healthy carriers of HBV with appropriate prophylactic antiviral agents are allowed) symptomatic ascites or pleural effusion pneumonitis that has required a course of oral steroids to assist with recovery, or a history of interstitial lung disease pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study History of active tuberculosis History

2017 Clinical Trials

199. Screening Inhaled Allergen Challenge for Dermatophagoides Farinae

methacholine inhalation challenge as performed in the separate screening protocol within the prior 12 months (defined as provocative concentration of methacholine of 10 mg/ml or less producing a 20% fall in FEV1 (PC20 methacholine) Allergic sensitization to house dust mite (D. farinae) as confirmed by positive immediate skin prick test response Negative pregnancy test for females who are not s/p hysterectomy with oophorectomy or who have been amenorrheic for 12 months or more. Oxygen saturation of >94 (...) months. Exacerbation of asthma more than 2x/week which could be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma. Daily requirements for albuterol due to asthma symptoms (cough, wheeze, chest tightness) which would be characteristic of a person of moderate or severe persistent asthma as outlined in the current NHLBI guidelines for diagnosis and management of asthma (not to include prophylactic use

2017 Clinical Trials

200. Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Seve

of the study. Female subjects who are postmenopausal for at least 2 years or have undergone a complete hysterectomy, bilateral tubal ligation, and/or bilateral oophorectomy, or have a congenital sterility are considered not of childbearing potential Exclusion Criteria: Subject has participated in another study of an investigational medicinal product (IMP) or an investigational device within the previous 3 months or is currently participating in another study of an IMP or an investigational device Subject (...) has a history of chronic alcohol or drug abuse within the previous 6 months Subject has a history of significant cardiovascular, respiratory, gastrointestinal, hepatic, endocrine, renal, dermatological, neurological, psychiatric, hematological, or bleeding disorders Subjects with known Tuberculosis (TB) infection and at high risk of acquiring TB infection. Subjects with latent TB (LTB) who have not completed the prophylactic treatment regimen for LTB 3 months prior to enrollment Subject has

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>